EXECUTIVE
SUMMARY
i. Urinary Incontinence Management
a. Types and Causes
b. Patient Volumes
c. Diagnosis
i. Urodynamic Studies Products
ii. Office-Based Ultrasound Systems
d. Treatment
i. Stress Urinary Incontinence
Surgery Products
ii. Urethral Prostheses and Inserts
iii. Bulking Agents
iv. Pelvic Exercisers
v. Sacral Nerve Stimulators
vi. Incontinence Pharmaceuticals
e. Combined Market Analysis
Exhibit
ES-1: Types of Urinary Incontinence
Exhibit ES-2: Female Incontinence,
Patient Volumes Forecast, 2005-2010
Exhibit ES-3: Urinary Incontinence
Management Products, Combined Market Forecast, 2005-2010
1. URINARY INCONTINENCE MANAGEMENT
PRODUCTS
1.1
Types and Causes
1.1.1 Stress Urinary Incontinence
1.1.2 Urge Incontinence
1.1.3 Mixed Incontinence
1.1.4 Overflow Incontinence
1.1.5 Other Types of Incontinence
1.2
Providers and Treatment Sites
1.3
Patient Volumes
1.4
Diagnosis
1.4.1 Basic Evaluation
1.4.1.1 Patient History
1.4.1.2 Physical Examination
1.4.1.3 Post-Void Residual Volume
1.4.1.4 Urinalysis
1.4.1.5 Other Tests
1.4.1.6 Treatment Selection
1.4.2 Specialized Tests
1.4.2.1 Urodynamic Studies
1.4.2.1.1 Equipment and Suppliers
1.4.2.1.2 Procedures
1.4.2.2 Cystoscopy/Cystourethroscopy
1.4.2.2.1 Equipment and Suppliers
1.4.2.2.2 Procedures
1.4.2.3 Imaging
1.4.2.3.1 Equipment and Suppliers
1.4.2.3.2 Procedures
1.5
Treatment
1.5.1 Behavioral Therapy
1.5.1.1 Bladder Training
1.5.1.2 Pelvic Muscle Rehabilitation
1.5.1.2.1 Pelvic Muscle Exercises
1.5.1.2.2 Biofeedback
1.5.1.2.3 Vaginal Weight Training
1.5.1.2.4 Pelvic Floor Stimulation
1.5.2 Incontinence Therapy Systems
1.5.3 Drug Therapy
1.5.3.1 Urge Incontinence Drugs
1.5.3.1.1 Anticholinergic Agents
1.5.3.1.1.1 Detrol
1.5.3.1.1.2 Ditropan
1.5.3.1.1.3 Enablex
1.5.3.1.1.4 OXYTROL
1.5.3.1.1.5 SANCTURA
1.5.3.1.1.6 VESIcare
1.5.3.1.2 Tricyclic Agents
1.5.3.1.3 Calcium Channel Blockers
1.5.3.2 Stress Urinary Incontinence Drugs
1.5.3.2.1 Alpha-Adrenergic Agonists
1.5.3.2.2 Estrogen
1.5.3.2.3 Yentreve
1.5.3.3 Overflow Incontinence Drugs
1.5.3.4 Products in Development
1.5.3.4.1 Botulinum Toxin
1.5.3.4.2 Capsaicin
1.5.3.4.3 Fesoterodine
1.5.3.4.4 Other Approaches
1.5.4 Surgical Therapy
1.5.4.1 Bladder Neck Hypermobility
Treatment
1.5.4.1.1 Retropubic Urethropexy
1.5.4.1.2 Transvaginal Needle Bladder
Neck Suspension
1.5.4.1.3 Anterior Vaginal and Abdominal
Paravaginal Repairs
1.5.4.2 Intrinsic Sphincter Deficiency
Treatment
1.5.4.2.1 Sling Procedures
1.5.4.2.2 Tension-Free Vaginal Tape
Procedures
1.5.4.2.3 Artificial Urinary Sphincters
1.5.4.3 Detrusor Instability Treatment
1.5.4.3.1 Augmentation Intestinocystoplasty
1.5.4.3.2 Urinary Diversion
1.5.4.4 Outlet Obstruction Treatment
1.5.4.5 Surgery Enhancement Products
1.5.4.5.1 Bone Anchor Systems
1.5.4.5.2 Pubovaginal Slings
1.5.5 Periurethral Bulking Treatment
1.5.6 Urethral Prostheses and Inserts
1.5.7 Sacral Nerve Stimulators
1.5.8 Collagen Remodeling Systems
1.5.8.1 Renessa
1.5.8.2 SURx
1.6
Market Analysis
1.6.1 Combined Market Analysis
1.6.2 Diagnostic Incontinence Products
1.6.2.1 Urodynamic Studies Products
1.6.2.2 Office-Based Ultrasound Products
1.6.3 Therapeutic Incontinence Products
1.6.3.1 Stress Urinary Incontinence
Surgery Products
1.6.3.2 Urethral Prostheses and Inserts
1.6.3.3 Bulking Agents
1.6.3.4 Pelvic Exerciser Products
1.6.3.5 Sacral Nerve Stimulation Products
1.6.4 Incontinence Pharmaceuticals
Exhibit
1-1: The Female Urogenital System
Exhibit
1-2: Types of Urinary Incontinence
Exhibit 1-3: 2008, Stress Urinary
Incontinence Classification System
Exhibit 1-4: 2008, Drugs That
May Influence Bladder Function
Exhibit 1-5: Female Incontinence,
Patient Volumes Forecast, 2005-2010
Exhibit 1-6: 2008, Urodynamic
Tests and Applications
Exhibit 1-7: 2008, Selected Office-Based
Urodynamic Systems
Exhibit 1-8: Urodynamic Studies,
Procedure Volumes Forecast, 2005-2010
Exhibit 1-9: 2008, Selected Office-Based
Diagnostic Ultrasound Scanners
Exhibit 1-10: Office-Based Ultrasound
for Urologic Evaluation, Procedure Volumes Forecast, 2005-2010
Exhibit 1-11: 2008, Treatment Options
for Urinary Incontinence
Exhibit 1-12: Stress Urinary Incontinence
Treatment, Procedure Volumes Forecast, 2005-2010
Exhibit 1-13: Urge Incontinence
Treatment, Procedure Volumes Forecast, 2005-2010
Exhibit 1-14: 2008, Selected Behavioral
Therapy Products for Incontinence Treatment
Exhibit 1-15: 2008, Selected Developments
in Incontinence Drug Therapy
Exhibit 1-16: 2008, Bladder Neck
Hypermobility and Intrinsic Sphincter Deficiency, Surgical Treatment
Options
Exhibit 1-17: 2008, Transvaginal
Needle Suspension Treatments, by Type
Exhibit
1-18: 2008, Selected Pubovaginal Slings
Exhibit
1-19: 2008, Selected Bulking Agents
Exhibit
1-20: 2008, Selected Sacral Nerve Stimulators
Exhibit 1-21: Urinary Incontinence
Management Products, Combined Market Forecast, 2005-2010
Exhibit 1-22: Urodynamic Studies
Products, Market Forecast, 2005-2010
Exhibit 1-23: Office-Based Ultrasound
Systems, Market Forecast, 2005-2010
Exhibit 1-24: 2007, Office-Based
Ultrasound Systems Market, Share by Supplier
Exhibit 1-25: Stress Urinary Incontinence
Surgery Products, Market Forecast, 2005-2010
Exhibit 1-26: Urethral Prostheses
and Inserts, Market Forecast, 2005-2010
Exhibit 1-27: Bulking Agents, Market
Forecast, 2005-2010
Exhibit 1-28: 2007, Bulking Agents
Market, Share by Supplier
Exhibit 1-29: Pelvic Exerciser
Products, Market Forecast, 2005-2010
Exhibit 1-30: Sacral Nerve Stimulation
Products, Market Forecast, 2005-2010
Exhibit 1-31: Incontinence Pharmaceuticals,
Market Forecast, 2005-2010
Exhibit 1-32: 2007, Incontinence
Pharmaceuticals Market, Share by Supplier
2. COMPANY PROFILES
2.1 American Medical Systems Holdings,
Inc.
2.2 C.R. Bard, Inc.
2.3 B-K Medical APS/Analogic Corporation
2.4
Boston Scientific Corporation
2.5 GE Healthcare/General Electric
Company
2.6 Hitachi Medical Systems America,
Inc./Hitachi LTD
2.7 Johnson & Johnson
2.8 Pfizer, Inc.
2.9 Royal Philips Electronics NV
2.10 Siemens AG
APPENDIX:
COMPANY LISTING